Conference Track

2008 Update on the Use of Approved HCV Agents

Source: CCO Official Conference Coverage of the 2008 AASLD Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Adding Metformin to Standard Peginterferon alfa-2a/Ribavirin Regimen Improves Insulin Sensitivity in Patients With HCV Infection
Induction Therapy With High-Dose Peginterferon alfa-2b Does Not Improve SVR Rates in Treatment-Naive Patients With Genotype 1 HCV Infection
Use of Growth Factors to Prevent Peginterferon alfa-2b/Ribavirin Dose Reductions Does Not Improve Overall SVR Rates in Small Genotype 1 HCV Study
Meta-analysis of 12 Randomized Controlled Trials Confirms Benefit of Extended Genotype 1 HCV Peginterferon alfa/ribavirin Treatment to 72 Weeks for Slow Responders
Low SVR Rates for Treatment-Naive Genotype 1 HCV-Infected Patients With Advanced Fibrosis or Cirrhosis at Baseline: Results of Canadian POWeR Study
Lower Relapse Rate With 72 vs 48 Weeks of Peginterferon alfa-2b Plus Ribavirin for Chronic Genotype 1 HCV-Infected Patients With Late Viral Response
Higher SVR Rates for Patients With Advanced Fibrosis/Cirrhosis Infected With Genotype 2 vs Genotype 3 HCV Following Treatment With Peginterferon alfa-2a and Ribavirin
4-Week Nonresponse to Peginterferon alfa/Ribavirin Predicts HCV-Infected Patient’s Failure to Achieve SVR
Insulin Resistance Associated With Lower Probability of SVR in HCV-Infected Patients Treated With Peginterferon alfa/Ribavirin
Decreased Ribavirin Exposure an Independent Predictor of Relapse in HCV Patients Receiving Peginterferon alfa-2a/Ribavirin

Expert Analysis

2008 Update on the Use of Approved HCV Agents

Faculty:

Gregory T. Everson, MD, FACP
Carroll Leevy, MD
K. Rajender Reddy, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize new data on the efficacy and safety of approved antiviral agents for the treatment of chronic hepatitis C
Discuss recent findings on the role of adjuvant therapy to improve the efficacy and safety of approved anti-HCV agents
Describe the latest insights into factors associated with sustained virologic response to therapy for chronic hepatitis C

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: January 07, 2009

Expiration Date: January 06, 2010

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.